Deoxyspergualin preferentially inhibits the growth and maturation of anti-CD40-activated surface IgD+ B lymphocytes

Clinical and Experimental Immunology

Volumn 112, Issue 3, 1998, Pages 495-500

  Morikawa, K ^a   Nemoto, K ^b   Miyawaki, T ^c   Morikawa, S ^a  

^a SHIMANE UNIVERSITY   (Japan)

^b NIPPON KAYAKU CO LTD   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

Author keywords

B lymphocytes; Cellular differentiation; Cellular proliferation; Human; Immunomodulators

Indexed keywords

15 DEOXYSPERGUALIN; CD40 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; METHYLDEOXYSPERGUALIN; MONOCLONAL ANTIBODY; SPERGUALIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCTION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL DIVISION; CELLS, CULTURED; GUANIDINES; HUMANS; IMMUNOGLOBULIN D; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-4;

EID: 0031805170     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1998.00602.x     Document Type: Article

References (31)

1. Maeda K, Umeda Y, Sailno T. Synthesis and background chemistry of 15-deoxyspergualin. Immunomodulating drugs. Ann NY Acad Sci 1993; 685:123-204.
2. Walter P, Thies J, Harbauer G et al. Allogeneic heart transplantation in the rat with a new antitumoral drug 15-deoxyspergualin. Transplant Proc 1986; 18:1293-4.
3. Schubert G, Stoffregen C, Timmermann W et al. Comparison of the new immunosuppressive agent 15-deoxyspergualin and cyclosporin A after highly allogeneic pancreas transplantation. Transplant Proc 1987; 19:3978-9.
4. Amemiya H, Suzuki S, Ota K et al. A novel rescue drug, 15-deoxyspergualin. Transplantation 1990; 49:337-43.
5. Ohlman S, Zilg H, Schindel F et al. Pharmacokinetics of 15-deoxyspergualin studied in renal transplant patients receiving the drug during graft rejection. Transplant Int 1994; 7:5-10.
6. Hoeger PH, Tepper MA, Faith A et al. Immunosuppressant deoxyspergualin inhibits antigen processing in monocytes. J Immunol 1994; 153:3908-16.
7. Nemoto K, Abe F, Nakamura T et al. Blastogenic responses and the release of interleukins 1 and 2 by spleen cells obtained from rat skin allograft recipients administered with 15-deoxyspergualin. J Antibiotics 1987; 40:1062-4.
8. Waaga AM, Urichs K, Krzysmanski M et al. The immunosuppressive agent 15-deoxyspergualin induces tolerance and modulates MHC-antigen expression and interleukin-1 production in the early phase of rat allograft responses. Transplant Proc 1990; 22:1613-4.
9. Takasu S, Sakagami K, Monsaki F et al. Immunosuppressive mechanism of 15-deoxyspergualin on sinusoidal lining cells in swine liver transplantation: suppression of MHC class II antigens and interleukin-1 production. J Surg Res 1991; 51:165-9.
10. Wang B, Benooist C, Mathis D. The immunosuppressant 1,5-deoxyspergualin reveals commonality between PreT and PreB cell differentiation. J Exp Med 1996; 183:2427-36.
11. Tepper MA, Nadler S, Massucco C et al. 15-deoxyspergualin, a novel immunosuppressive drug: studies of the mechanism of action. Ann NY Acad Sci 1993; 685:136-47.
12. Nadler SG, Tepper MA, Schacter B et al. Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heart shock proteins. Science 1992; 258:484-6.
13. Nadeau K, Nadler SG, Saulnier M et al. Quantitation of the interaction of the immunosuppressant deoxyspergualin and analogs with Hsp70 and Hsp90. Biochem 1994; 33:2561-7.
14. Tepper MA, Nadler SG, Esselstyn JM et al. Deoxyspergualin inhibits κ light chain expression in 70z/3 pre-B cells by blocking lipopolysaccharide-induced NF-kB activation. J Immunol 1995; 155:2427-36.
15. Tepper MA, Petty B, Bursuker I et al. Inhibition of antibody production by the immunosuppressive agent, 15-deoxyspergualin. Transplant Proc 1991; 23:328-31.
16. Morikawa K, Oseko F, Morikawa S. The suppressive effect of deoxyspergualin on the differentiation of human B lymphocyte maturing into immunoglobulin-producing cells. Transplantation 1991; 54:526-31.
17. Wortis HH, Teutsch M, Higer M et al. B-cell activation by crosslinking of surface IgM or ligation of CD40 involves alternative signal pathways and results in different B-cell phenotypes. Proc Natl Acad Sci USA 1995; 92:3348-52.
18. Defrance T, Vanbervliet B, Briere F et al. Interleukin 10 and transforming growth factor cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J Exp Med 1992; 175:671-82.
19. Rousset F, Garcia H, Banchereau J. Cytokine-induced proliferation and immunoglobulin production of human B lymphocytes triggered through their CD40 antigen. J Exp Med 1991; 173:705-10.
20. Galibert L, Durand I, Banchereau J et al. CD40-activated surface IgD-positive lymphocytes constitute the long term IL-4-dependent proliferating B cell pool. J Immunol 1993; 152:22-29.
21. Preud'homme JL. Loss of surface IgD by human B lymphocytes during polyclonal activation. Eur J Immunol 1977; 7:191-3.
22. +) B cells to secrete IgG1 and IgG3. J Exp Med 1994; 179:757-62.
23. Nonoyama S, Hollenbaugh D, Aruffo A et al. B cell activation via CD40 is required for specific antibody production by antigen-stimulated human B cells. J Exp Med 1993; 178:1097-102.
24. Silvy A, Lagresle C, Bella C et al. The differentiation of human memory B cells into specific antibody-secreting cells is CD40 independent. Eur J Immunol 1996; 26:517-24.
25. Gray D, Dullforce P, Jainandunsing S. Memory B cell development but not germinal center formation is impaired by in vitro blockade of CD40-CD40 ligand interaction. J Exp Med 1994; 180:141-55.
26. Liu Y-J, Johnson GD, Gordon J et al. Germinal centres in T-cell-dependent antibody responses. Immunol Today 1992; 13:17-21.
27. Nicholson IC, Brisco MJ, Zola H. Memory B lymphocytes in human tonsil do not express surface IgD. J Immunol 1995; 154:1105-13.
28. Bacuerle PA, Henkel T. Function and activation of NF-κ B in the immune system. Annu Rev Immunol 1994; 12:141-79.
29. Neumann M, Wohlleben G, Chuvpilo S et al. CD40, but not lipopolysaccharide and anti-IgM stimulation of primary B lymphocytes, lead to a persistent nuclear accumulation of Re1B. J Immunol 1996; 157:4862-9.
30. Atkinson K. Clinical spectrum of human chronic graft-vs.-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J et al., eds. Graft-vs.-host disease: immunology, pathophysiology, and treatment. New York: Marcel Dekker, 1990:569-86.
31. Schorlemmer H-U, Dickneite G. Preclinical studies with 15-deoxyspergualin in various animal models for autoimmune diseases. Ann NY Acad Sci 1993; 685:155-74.